Skip to content
Screener

United Therapeutics UTHR Q1 2025 earnings

Reported April 30, 2025 · Before market open

Revenue$794.4MBeat by $15.7M
EPS$6.63Beat by $0.34
Revenue estimate$778.7M
EPS estimate$6.29

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$789.5M
EPS estimate$6.44

Financials

Q1 2025

Income statement

See full
Revenue$794.4M+17.2%
Gross profit$701.9M+16.1%
Operating income$382.8M+7.4%
Net income$322.2M+5.1%
EPS (diluted)$6.63+7.5%

Balance sheet

See full
Cash & equivalents$1.9B+51.8%
Total equity$6.8B+27.5%
Total assets$7.7B+19.2%

Cash flow

See full
Operating cash flow$461.2M+22.5%
CapEx$74.9M+96.1%
Free cash flow$386.3M+14.2%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$13.85B+28.2%
P/E11.4×+1.2×
P/S4.6×+0.3×

Profitability

See full
Gross margin89%+0.1pp
Operating margin46.9%-3.4pp
Net margin40.4%-1.6pp
FCF margin37.7%+7.6pp

Returns & leverage

See full
Return on equity19.9%-0.1pp
Current ratio5.5×+1.7×

Segments

By product

See full
Tyvaso DPI$302.5M+33.0%
Nebulized Tyvaso$163.8M+13.0%
Remodulin$138.2M+8.0%
Orenitram$120.7M+13.7%
Unituxin$58.2M-0.3%

By geography

See full
U.S.$749.6M—

FAQ

When did United Therapeutics report Q1 2025 earnings?
United Therapeutics (UTHR) reported Q1 2025 earnings on April 30, 2025 before market open.
What were United Therapeutics's Q1 2025 revenue and EPS?
United Therapeutics reported revenue of $794.4M and eps of $6.63 for Q1 2025.
Did United Therapeutics beat estimates in Q1 2025?
Revenue beat the consensus estimate of $778.7M by $15.7M. EPS beat the consensus estimate of $6.29 by $0.34.
How did United Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 17.2% from $677.7M a year earlier and eps grew 7.5% from $6.17.
Where can I find United Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-039710) and the 10-Q periodic report (0001082554-25-000023) directly on SEC EDGAR. The filing index links above go to sec.gov.